The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Importance Worldwide, the burden of heart failure has increased to an estimated 23 million
people, and approximately 50% of cases are HF with reduced ejection fraction (HFrEF) …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …

Heart failure (HF) has been recognized as a common complication of diabetes, with a
prevalence of up to 22% in individuals with diabetes and increasing incidence rates. Data …

Natriuretic peptide [NP; B‐type NP (BNP), N‐terminal proBNP (NT‐proBNP), and
midregional proANP (MR‐proANP)] concentrations are quantitative plasma biomarkers for …

Background: Diagnosis of heart failure with preserved ejection fraction (HFpEF) is
challenging in euvolemic patients with dyspnea, and no evidence-based criteria are …

Diagnosing heart failure is often difficult due to the non‐specific nature of symptoms, which
can be caused by a range of medical conditions. Natriuretic peptides (NPs) have been …

Natriuretic peptides, brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of
brain natriuretic peptide (NT-proBNP) are globally and most often used for the diagnosis of …

Background We examined the longitudinal associations between changes in cardiovascular
biomarkers and cancer therapy–related cardiac dysfunction (CTRCD) in patients with breast …